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4.0/).1. Introduction
Accurate prosthetic valve assessment is of great impor-
tance for clinical decisions. Current guidelines recommend
noninvasive evaluation in patients with tricuspid prosthetic
valves (TPV) with Doppler echocardiography.1 Normal
Doppler derived indices such as transprosthetic peak ve-
locity, mean transprosthetic pressure gradient and pressure
half time (PHT) have been reported, although not vali-
dated. Studies using large series of early postoperative dataaragiannis, MD, FASE, FACC,
General Army Hospital of
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cal Society. Publishing services by
licenses/by-nc-nd/4.0/).have proposed additional parameters and clinically helpful
algorithms to evaluate both bioprosthetic and mechanical
valves in the tricuspid position.2,3 The addition of newer
techniques such as three-dimensional echocardiography
may also add value to traditional tricuspid prosthetic valve
evaluation. The purpose of this review is to focus on these
new proposed indices to better describe the nature of
pathologic TPV dysfunction.
2. Echocardiographic Evaluation of Tricuspid
Prosthetic Valve Function
2.1. 2D Echocardiography
Comprehensive evaluation either with transthoracic echo-
cardiography (TTE) or transesophageal echocardiographyElsevier B.V. This is an open access article under the CC BY-NC-ND
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structure. Standard transthoracic (RV inflow, four chamber,
RV inflow-outflow and subcostal views) and transesophageal
views (mid-esophageal (ME) 4 chamber, the ME inflow-
outflow, the ME-modified bicaval TV and the transgastric
(TG) RV inflow-outflow view)4 can visualize the appropriate
seating of the TPV in the annulus, diagnose TPV degener-
ation due to leaflet calcification and thickening and
possibly identify causes of obstruction (thrombus, pannus,
vegetation) or regurgitation (vegetation, dehiscence).
Transthoracic imaging can provide excellent quality images
because the tricuspid valve is an anterior structure. 2D
echocardiography may also provide additional information
about RV and RA size and function, which results in an in-
tegrated approach to evaluate the presence and severity of
TPV dysfunction.
2.2. Color Doppler Imaging
Color Doppler shows the blood flow pattern across the
prostheses. In bioprosthetic TPVs the diastolic flow jet is
smooth and wide, with no apparent aliasing. In mechanical
TPVs, the antegrade color Doppler jet direction and pattern
may differ among variable valve types (ball cage, bileaflet
valves). Color Doppler is also the preferred method for
assessing TPV transprosthetic and periprosthetic regurgi-
tation. Mild regurgitant washing jets are apparent in nor-
mally functioning mechanical TPVs, while mild regurgitant
transprosthetic jets might be rarely seen in normally
functioning bioprosthetic TPVs early post-surgery. Acoustic
shadowing from the valve’s metallic elements may inter-
fere with color Doppler interrogation, and views with
minimal shadowing are preferred with TTE (the RV inflow
and the subcostal views). Multiplane TEE may offer addi-
tional views, avoiding acoustic shadowing, especially in
cases when significant transprosthetic or periprosthetic
regurgitation is suspected.
2.3. Spectral Doppler Echocardiography
Doppler echocardiography is currently recommended for
TPV evaluation early post implantation.1 The trans-
prosthetic velocity can be noninvasively estimated with
continuous wave (CW) Doppler and pressure gradient (peak
and mean) can be estimated by applying the simplified
Bernoulli equation. Adequate Doppler alignment with flow
appears to be superior with traditional TTE views, whereas
valve interrogation with CW by the TEE approach might be
challenging in some cases. Current guidelines1 report
normal transprosthetic gradient and pressure half time
values; however, additional Doppler derived parameters
such as the effective orifice area (EOA) and time velocity
integral (TVI) ratio have been recently described in larger
population studies2,3 to provide a comprehensive evalua-
tion of TPV function.
Respiratory transprosthetic velocities may vary during
the respiratory cycle; therefore, Doppler measurements
from at least five cycles have been proposed to be averaged
in current guidelines whether the patient is in sinus rhythm
or atrial fibrillation. In cases of significant Doppler velocity
variation, more cycles might be averaged.12.4. Mean Gradient
Current guidelines state that normally functioning tricuspid
prostheses have a mean gradient <6mmHg.1 Recently,
Blawet et al. have shown that a transvalvular mean
gradient <9mmHg identifies normally functioning bio-
prosthetic tricuspid valves.2 They included a variety of
different types of valves and sizes (Carpentier-Edwards
Duraflex, Medtronic Mosaic, St. Jude Medical Biocor,
Carpentier-Edwards Perimount and Medtronic Hancock II).
In another study evaluating mechanical tricuspid bileaflet
valves, a mean gradient <6 mmHg reflected normally
functioning valves.3 However, it should be noted that the
mean gradient may be altered significantly in high flow
states (anemia, hyperthyroidism, sepsis), where the valves
are still functioning normally despite higher reported gra-
dients.1 Other conditions such as constrictive pericarditis or
elevated right ventricular diastolic pressures can also
affect transprosthetic gradients. Although high right atrial
pressure or a noncompliant right atrium can affect the
contour of the continuous wave Doppler in cases of
tricuspid regurgitation reflecting the relation of pressures
across the prosthesis, their contribution to the trans-
valvular diastolic mean gradient assessment remains
unclear.
2.5. Pressure Half-Time
Pressure half time (PHT) is the time it takes for the
transprosthetic peak gradient measured by Doppler to
decline to half of its initial value. Current guidelines
recommend that a PHT<230 msec indicates the absence of
significant valve stenosis.1 It should be noted, that rounded
spectral Doppler contours are not uncommon and PHT
cannot be reliably evaluated in these cases. The normal
value of 200-238 msec has been proposed as an upper limit
for bioprosthetic TVPs.5,6 Blawet et al recently showed that
normally operating bioprostheses in the tricuspid position
have a PHT <200 msec.2 Different values have been pub-
lished for the normal mechanical tricuspid prostheses. In a
recent study, a PHT<130 msec was associated with normal
function in bileaflet mechanical tricuspid prostheses (St.
Jude Medical Standard, CarboMedics Standard).3 This is
consistent with previously published reports, where the
mean PHT ranged between 102-120 msec for St Jude
bileaflet mechanical valves (St. Jude Medical Standard).7,8
In a past study in which older prostheses types were used,
Conolly et al. demonstrated that mean PHT for normal ball
caged valves was 144 46 msec.5
2.6. TVI Ratio for Tricuspid Prosthetic Valves
Similar to mitral mechanical prosthetic valves, a ratio of
(TVITPV) to the left ventricle outflow tract TVI (TVILVOT) has
been investigated as a useful index of tricuspid prosthetic
valve function. Blauwet et al. demonstrated that a peak
tricuspid E velocity <2.1 m/sec, TVITPV/TVILVOT<3.3 and
PHT<200msec were predictive of normal TPV function in
tricuspid valve bioprostheses.2 The same group has also
proposed the use of the TVI ratio for the evaluation of
mechanical tricuspid valve prostheses. A peak tricuspid E
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msec was found to be predictive of normal mechanical TPV
function.3
2.7. Effective Orifice Area (EOA)
Effective orifice area (EOA) represents the area through
which streamline or frictionless flow occurs, and it has been
traditionally evaluated by echocardiography either using
the pressure half time or the continuity equation method.
However, the use of either the continuity equation or the
pressure half time method to calculate EOA for TPVs has
not been validated with in vitro data. In a small study
including only five TPVs, Fawsy et al., using both echocar-
diography and catheterization data, demonstrated that
EOAZ 190/PHT by echocardiography compares well with
the invasively derived EOA.9 Recent comprehensive Doppler
echocardiography retrospective studies have shown that
EOA calculated by the pressure half time method was larger
than the one calculated with the continuity equation.2,3
Those studies have also proposed normal reference values
for bioprosthetic and mechanical valve EOA in the tricuspid
position.Figure 1 The figure shows a two-dimensional (2D) and continuous
(red arrow) in a 66-year-old female and the same valve one month la
a normal mechanical tricuspid valve in the apical four-chamber v
measured at a heart rate of 86 bpm. Panel B: 2D and CW in an obstru
one month later due to valve thrombosis. Severely elevated transp
rate of 97 bpm.3. Tricuspid Prosthetic Valve Obstruction
Both tricuspid bioprostheses and tricuspid mechanical
valves may fail early or late after implantation. Common
mechanisms of valve obstruction include leaflet degenera-
tion, pannus formation, thrombus or vegetation obstructing
transvalvular flow (Figure 1). Bioprosthetic TPV obstruction
is not uncommon and occurs due to leaflet thickening and
calcification. It has been reported that leaflet degeneration
varies between 0.4 and 2.2% patient-years in previously
published studies.10,11 Mechanical TPVs are commonly
obstructed by thrombus or pannus formation, and throm-
bosis has been reported at 0.5%-3.3% patient-years in
earlier studies.11e13 Doppler measurements have been
shown to accurately predict TPV stenosis when compared
with invasive hemodynamic data.14,15 Current guidelines
recommend 2D echocardiography and Doppler derived pa-
rameters to assess TPV dysfunction due to valve stenosis.1
3.1. 2D Echocardiography
Both TTE and TEE may verify abnormal leaflet structure due
to degeneration with calcification and abnormal motion,-wave (CW) examination of a normal mechanical tricuspid valve
ter after acute thrombosis. Panel A: 2D and CW examination of
iew. Normal transprosthetic mean gradient of 2.8 mmHg was
cted mechanical tricuspid valve (red arrow) of the same female
rosthetic mean gradient of 15 mmHg was measured at a heart
Figure 2 The figure shows the transesophageal echocardio-
gram (TEE) images from a 40-year-old woman with moderate
prosthetic valve regurgitation. Severely thickened and calci-
fied leaflets and moderate tricuspid regurgitation in a degen-
erated tricuspid bioprosthesis (red arrow).
148 D. Maragiannis et al.with visualization of vegetations or thrombi when present.
TEE may also measure thrombus size and impact the deci-
sion on whether to use thrombolytic therapy.16
3.2. Color Flow Imaging
Color Doppler may add supportive information to TPV
evaluation. Obstructive flow is usually turbulent and ap-
pears as a high velocity narrow color jet with aliasing. A
flow convergence zone may be noted proximal to the right
atrium, although acoustic shadowing may conceal this
finding.
3.3. Spectral Doppler
In a large series of patients with different types of tricuspid
bioprostheses during the early postoperative period, Bla-
wet et al. have demonstrated that a PHT 200 msec is
predictive of valve stenosis.2 These findings are in line with
current guidelines (PHT>230 msec).1 In another study, the
same group has reported that a PHT130 msec identifies
obstructed bileaflet tricuspid mechanical valves.3 Additive
parameters to the diagnosis of TPV obstruction are elevated
mean gradient 9 mmHg, which is highly suggestive of
tricuspid bioprosthetic valve stenosis, and 6 mmHg in
mechanical TPVs, an elevated velocity 2.1 m/sec in
tricuspid bioprostheses, whereas an abnormal value for
mechanical bileaflet prostheses has been reported to be
1.9 m/sec. An abnormal EOA is also supportive of TPV
obstruction.2,3
4. Tricuspid Valve Patient Prosthesis Mismatch
Patient prosthesis mismatch (PPM) occurs when the pros-
thesis is small for a patients’ body size. Clinically, it pre-
sents with an elevated transprosthetic valve gradient and a
small valve EOA. Blawet et al. defined PPM as an indexed
EOA (iEOA) <1.2 cm2/m2. Severe PPM was defined as iEOA
0.9 cm2/m2.2,3 A PHT200 msec for bioprosthetic and
130 msec for mechanical tricuspid valve prostheses can
differentiate the obstructed TPV from one with PPM.
5. Tricuspid Prosthetic Valve Regurgitation
TTE is the primary technique to diagnose pathologic
tricuspid prosthetic valve regurgitation. TEE may offer
additional information, showing the cause and the location
of regurgitation when TTE is not diagnostic. Current
guidelines recommend an integrated approach to quantify
regurgitation using 2D, color Doppler and spectral Doppler
parameters.1 Pathologic regurgitation can occur in both
bioprosthetic and mechanical tricuspid prostheses
(Figure 2). However, no echocardiographic parameters
associated with significant pathologic prosthetic tricuspid
paravalvular or transprosthetic regurgitation have been
reported in clinical studies. In bioprosthetic valves, trans-
prosthetic regurgitation is usually caused by valve degen-
eration with thickening and calcification of valve leaflets or
leaflet perforation due to endocarditis. In mechanical
prostheses, pathologic regurgitation may occur whenpannus, thrombus or vegetation prevent complete leaflet
closure. Paravalvular tricuspid regurgitation, although rare,
occurs when blood leaks backward during systole outside
the prosthetic ring. Paravalvular regurgitation reflects
usually suture loosening or infective endocarditis with the
presence or absence of abscess formation.
A limited amount of regurgitation is normal in mechanical
tricuspid prostheses. Regurgitant jets have a low velocity
profile, they appear smooth and homogenous with color
Doppler, and they are of short duration. Their flow pattern
varies within different valve types. Regurgitation is not
usually present in bioprosthetic valves; however, in the early
postoperative period, some trace of backflow may be seen.
5.1. 2D Echocardiography
2D echocardiography using standard views with either TTE
or TEE may provide a clear delineation of prosthetic valve
pathology and etiology of regurgitation (dehiscence,
degeneration, endocarditis, mechanical leaflet fixed in an
open position). Identifying the cause of regurgitation is
extremely important because clinical decisions will be
based upon the echocardiographic diagnosis. The presence
of substantial enlargement in the right chamber is sup-
portive of significant prosthetic valve regurgitation
although other causes may commonly affect the size of the
right chamber. Inferior vena cava dilatation is also associ-
ated with significant TPV regurgitation.
5.2. Color Flow Imaging
Although color Doppler has proven to be a useful method
for quantifying regurgitant lesion severity in native
tricuspid valves, its value in pathologic TPV regurgitation
may be more limited due to acoustic attenuation and re-
verberations by the prosthesis. Importantly, TTE can iden-
tify transprosthetic or paravalvular regurgitation, assess
qualitatively and quantitatively the severity of
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vena contracta measurements. Similar to native valves, a
vena contracta width >0.7 cm is highly specific and sensi-
tive for severe TR.1 An alternative strategy involving TEE
may add more precise information about regurgitant jet
location and its direction and size, especially when TTE is
not conclusive.
5.3. Spectral Doppler
Spectral Doppler derived parameters should be considered
in addition to 2D and color flow imaging. An elevated
tricuspid peak E velocity (1.9 m/sec in bioprosthetic or
2.1 m/sec in mechanical TPVs) and a holosystolic flow
reversal in hepatic venous flow by Pulse Wave (PW) Doppler
are associated with significant regurgitation. However,
existing data suggest that both parameters may not be al-
ways specific for severe TR. Another common feature of
severity by continuous wave (CW) Doppler is a dense, early
peaking jet. Recently, Blawet et al. have reported that
spectral Doppler parameters increase the confidence of
identifying severe regurgitant lesions. With severe bio-
prosthetic TR, peak tricuspid E velocity is usually 2.1 m/Figure 3 Three-dimensional transesophageal echocardiography (T
the tricuspid position. Panel A, B: Two-dimensional orthogonal lon
data. Panel C: Short axis (en face) view of the valve surgical ring. Pa
bioprosthetic valve.sec, with TVITPV/TVILVOT ratio 3.3 and PHT<200 msec.2
For severe mechanical TR, peak tricuspid E velocity is
1.9 m/sec, TVITPV/TVILVOT ratio 2.0 and PHT<130 msec.3
In summary, dehiscence of the prosthesis by 2D echo-
cardiography, a wide vena contracta width (0.7 cm) and
/or the presence of significant flow convergence zone when
combined with dilated right heart chambers are all sup-
portive of severe tricuspid prosthetic valvular or para-
valvular regurgitation. Spectral Doppler parameters
previously described may enhance the confidence of the
diagnosis.
6. 3D Echocardiography
Multiplane TEE is indicated for the evaluation of prosthetic
valve regurgitation (severity and mechanism), the evalua-
tion of suspected valve obstruction (presence of thrombus
or pannus), the evaluation of endocarditis and associated
abnormalities (vegetation, valve abscess, fistula, pseudoa-
neurysm) and for guidance of transcatheter procedures.4
3D TTE and TEE offer additional diagnostic value in iden-
tifying pathologic TPVs (Figure 3). A very limited number of
studies have addressed the role of novel technology inEE) of a normally functioning 10-year-old bioprosthetic valve in
g planes of the bioprosthetic valve, created by the volumetric
nel D: 3D volume data, showing the thin leaflets of the tricuspid
150 D. Maragiannis et al.prosthetic valve evaluation in the last decade, but the
number of the TPVs evaluated in these studies was very
small.17,18 According to recently published guidelines, the
native tricuspid valve’s evaluation is enhanced by 3D
echocardiography at the mid-esophageal 4 chamber-view
from 0o to 30o or at the 40o transgastric view using a
narrow-angle or a wide-angle acquisition with either a
single-beat or multiple-beat acquisition.4,19 Dehiscence
locations, regurgitant jet sites, vegetations, degenerative
leaflets, thrombi and immobile leaflets can be identified by
3D TEE.20,21 The limited temporal and spatial resolution are
inherent limitations of 3D echocardiography. Stitching ar-
tifacts are also prominent in patients with arrhythmias.
Further research is needed to investigate the diagnostic
role of 3D echocardiography in evaluating TPV structure
and function.7. Tricuspid Transcatheter Valve-in-valve
Implantation
2D and 3D TEE have been successfully used for the
deployment of percutaneous transcatheter valves in
severely dysfunctional bioprosthetic TPVs in high surgical
risk patients using the transatrial, transjugular or trans-
femoral approach. TEE is the modality of choice during
transcatheter valve in valve implantation.4 Only a few
cases in literature22e29 have been reported, mostly
describing implantation of either the Melody valve (Med-
tronic, Inc., Minneapolis, MN, USA) or Edwards SAPIEN
transcatheter valve (Edwards Lifesciences, Irvine, CA,
USA). Currently, Doppler parameters and normal reference
values from surgical prosthetic valves are used in clinical
practice to assess percutaneous valve function; however,
additional data on the hemodynamic performance of these
valves using Doppler derived parameters in larger patient
populations are needed.8. The role of other modalities
An ECG gated multidetector computed tomography col-
lecting 3D dataset may reconstruct and visualize the valve
anatomy, paravalvular regurgitation on any plane, identify
abscesses, thrombus or pannus in most cases on an offline
analysis system. MDCT is an accurate modality for identi-
fying the mechanism of valve obstruction; however, radia-
tion, contrast use and artifacts from the prostheses are still
a concern.
CMR may provide anatomic (anatomic orifice area by
planimetry) and functional information (peak velocity
through the valve, calculation of regurgitant volume/frac-
tion). By using volumetric data from the right ventricle
ejection fraction calculation and the phase contrast mea-
surement of flow through the pulmonary artery, CMR may
evaluate tricuspid regurgitant volume/fraction. However,
both bioprosthetic and (especially) mechanical valves
generate significant metallic artifacts, which creates diffi-
culties in interpretation. Phase contrast measurement of
through plane velocity can be underestimated if it is not
perpendicular to the flow direction and should be measured
at the location of maximal velocity. The temporalresolution of CMR is lower than continuous wave Doppler,
and annular motion during cardiac cycle generates addi-
tional sources of error for velocity measurements. To our
knowledge, there are no published reports describing the
accuracy of CMR measurements for tricuspid valve
prostheses.
9. Conclusion
Echocardiography is the primary diagnostic modality for
the evaluation of tricuspid prosthetic valve function. Early
postoperative examination and comparative echocardio-
graphic follow-up studies may unmask possible valve
dysfunction. In the era of multimodality imaging, echo-
cardiography remains a widely available inexpensive
method with enough evidence incorporated in current
guidelines to accurately evaluate tricuspid prosthetic
valve function. The diagnostic role of 3D echocardiogra-
phy to the routine assessment of tricuspid prosthetic
valves warrants further investigation in larger population
studies.References
1. Zoghbi WA, Chambers JB, Dumesnil JG, et al. Recommenda-
tions for evaluation of prosthetic valves with echocardiography
and Doppler ultrasound: a report From the American Society of
Echocardiography’s Guidelines and Standards Committee and
the Task Force on Prosthetic Valves, developed in conjunction
with the American College of Cardiology Cardiovascular Imag-
ing Committee, Cardiac Imaging Committee of the American
Heart Association, the European Association of Echocardiog-
raphy, a registered branch of the European Society of Cardi-
ology, the Japanese Society of Echocardiography and the
Canadian Society of Echocardiography, endorsed by the
American College of Cardiology Foundation, American Heart
Association, European Association of Echocardiography, a
registered branch of the European Society of Cardiology, the
Japanese Society of Echocardiography, and Canadian Society
of Echocardiography. J Am Soc Echocardiogr. 2009;22:
975e1014.
2. Blauwet LA, Danielson GK, Burkhart HM, et al. Comprehensive
echocardiographic assessment of the hemodynamic parame-
ters of 285 tricuspid valve bioprostheses early after implanta-
tion. J Am Soc Echocardiogr. 2010;23:1045e1059.
3. Blauwet LA, Burkhart HM, Dearani JA, et al. Comprehensive
echocardiographic assessment of mechanical tricuspid valve
prostheses based on early post-implantation echocardiographic
studies. J Am Soc Echocardiogr. 2011;24:414e424.
4. Hahn RT, Abraham T, Adams MS, et al. Guidelines for per-
forming a comprehensive transesophageal echocardiographic
examination: recommendations from the American Society of
Echocardiography and the Society of Cardiovascular Anesthe-
siologists. J Am Soc Echocardiogr. 2013;26:921e964.
5. Connolly HM, Miller Jr FA, Taylor CL, Naessens JM, Seward JB,
Tajik AJ. Doppler hemodynamic profiles of 82 clinically and
echocardiographically normal tricuspid valve prostheses. Cir-
culation. 1993;88:2722e2727.
6. Aoyagi S, Tomoeda H, Kawano H, Yokose S, Fukunaga S.
Doppler echocardiographic evaluation of prosthetic valves in
tricuspid position. Asian Cardiovasc Thorac Ann. 2003;11:
193e197.
7. Aoyagi S, Nishi Y, Kawara T, Oryoji A, Kosuga K, Ohishi K.
Doppler echocardiographic evaluation of St. Jude Medical
Tricuspid Prosthetic Valve Evaluation 151valves in the tricuspid position. J Heart Valve Dis. 1993;2:
279e286.
8. Sezai A, Shiono M, Akiyama K, et al. Doppler echocardiographic
evaluation of St. Jude Medical valves in the tricuspid position:
criteria for normal and abnormal valve function. J Cardiovasc
Surg. 2001;42:303e309.
9. Fawzy ME, Mercer EN, Dunn B, al-Amri M, Andaya W. Doppler
echocardiography in the evaluation of tricuspid stenosis. Eur
Heart J. 1989 Nov;10(11):985e990.
10. Ratnatunga CP, Edwards MB, Dore CJ, Taylor KM. Tricuspid
valve replacement: UK Heart Valve Registry mid-term results
comparing mechanical and biological prostheses. Ann Thorac
Surg. 1998;66:1940e1947.
11. Garatti A, Nano G, Bruschi G, et al. Twenty-five year outcomes
of tricuspid valve replacement comparing mechanical and
biologic prostheses. Ann Thorac Surg. 2012;93:1146e1153.
12. Nakano K, Koyanagi H, Hashimoto A, Ohtsuka G, Nojiri C.
Tricuspid valve replacement with the bileaflet St. Jude Medical
valve prosthesis. J Thorac Cardiovasc Surg. 1994;108:888e892.
13. Pe´terffy A, Szentkira´lyi I. Mechanical valves in tricuspid posi-
tion: cause of thrombosis and prevention. Eur J Cardiothorac
Surg. 2001;19:735e736.
14. Wilkins GT, Gillam LD, Kritzer GL, Levine RA, Palacios IF,
Weyman AE. Validation of continuous-wave Doppler echocar-
diographic measurements of mitral and tricuspid prosthetic
valve gradients: a simultaneous Doppler-catheter study. Cir-
culation. 1986;74:786e795.
15. Burstow DJ, Nishimura RA, Bailey KR, et al. Continuous wave
Doppler echocardiographic measurement of prosthetic valve
gradients. A simultaneous Doppler-catheter correlative study.
Circulation. 1989;80:504e514.
16. Tong AT, Roudaut R, Ozkan M, et al, Prosthetic Valve
Thrombolysis-Role of Transesophageal Echocardiography (PRO-
TEE) Registry Investigators. Transesophageal echocardiography
improves risk assessment of thrombolysis of prosthetic valve
thrombosis: results of the international PRO-TEE registry. J Am
Coll Cardiol. 2004;43:77e84.
17. Sugeng L, Shernan SK, Weinert L, et al. Real-time three-
dimensional transesophageal echocardiography in valve dis-
ease: comparison with surgical findings and evaluation of
prosthetic valves. J Am Soc Echocardiogr. 2008;21:1347e1354.18. Krim SR, Vivo RP, Patel A, et al. Direct assessment of normal
mechanical mitral valve orifice area by real-time 3D echocar-
diography. JACC Cardiovasc Imaging. 2012;5:478e483.
19. Lang RM, Badano LP, Tsang W, et al. EAE/ASE recommendations
for image acquisition and display using three-dimensional
echocardiography. Eur Heart J Cardiovasc Imaging. 2012;13:
1e46.
20. Naqvi TZ, Rafie R, Ghalichi M. Real-time 3D TEE for the diag-
nosis of right-sided endocarditis in patients with prosthetic
devices. JACC Cardiovasc Imaging. 2010;3:325e327.
21. Cheng HL, Cheng YJ, Wang YC, Fan SZ. A stenotic bioprosthetic
valve in the tricuspid position: real-time 3-dimensional trans-
esophageal echocardiography as a useful supplement to con-
ventional assessment. Anesth Analg. 2012;115:253e256.
22. Hon JK, Cheung A, Ye J, et al. Transatrial transcatheter
tricuspid valve-in-valve implantation of balloon expandable
bioprosthesis. Ann Thorac Surg. 2010;90:1696e1697.
23. Gurvitch R, Cheung A, Ye J, et al. Transcatheter valve-in-valve
implantation for failed surgical bioprosthetic valves. J Am Coll
Cardiol. 2011;58:2196e2209.
24. Hoendermis ES, Douglas YL, van den Heuvel AF. Percutaneous
Edwards SAPIEN valve implantation in the tricuspid position:
case report and review of literature. EuroIntervention. 2012;8:
628e633.
25. Gaia DF, Palma JH, de Souza JA, Buffolo E. Tricuspid trans-
catheter valve-in-valve: an alternative for high-risk patients.
Eur J Cardiothorac Surg. 2012;41:696e698.
26. Petit CJ, Justino H, Ing FF. Melody valve implantation in the
pulmonary and tricuspid position. Catheter Cardiovasc Interv.
2013 Dec 1;82(7):E944eE946.
27. Gerosa G, D’Onofrio A, Tessari C, Pittarello D, Rubino M,
Colli A. Open transcatheter tricuspid balloon expandable
valve-in-valve implantation for failed bioprosthesis. J Thorac
Cardiovasc Surg. 2013;146:e3ee5.
28. Ribichini F, Pesarini G, Feola M, et al. Transcatheter tricuspid
valve implantation by femoral approach in trivalvular heart
disease. Am J Cardiol. 2013;112:1051e1053.
29. Daneault B, Williams MR, Leon MB, Paradis JM, Kodali SK.
Transcatheter tricuspid valve-in-valve replacement resulting in
4 different prosthetic heart valves in a single patient. J Am Coll
Cardiol. 2013; Jan 15;61:e3.
